Mankind Pharma IPO

Complete Offer for Sale (OFS) of 40,058,844 Equity Shares.

[{"selector":"#anim-f983d0f0-6f1a-4c67-8931-c333f6157367","keyframes":{"transform":["translate3d(-117.47573%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-27f5b970-c39f-4525-81a1-9adc3f93de13","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9e035802-133e-431e-bb30-15bff3839929","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-0b76da31-cfd8-4535-bdc0-8e2363d96a73","keyframes":{"transform":["translate3d(118.54304%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5a7307b6-0c93-4c09-aef6-db09303e9533","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7cf5dc01-6237-4c1c-980e-490cd8b00ac0","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-a46d5c62-9ea1-4c45-a107-b1b93c4060b1","keyframes":{"transform":["scale(1)","scale(1.5)","scale(0.95)","scale(1)"],"offset":[0,0.33,0.66,1]},"delay":0,"duration":1450,"easing":"ease-in-out","fill":"both","iterations":1}] Learn more

Subscription Date - Apr 25, 2023 to Apr 27, 2023

Subscription Price - ₹1026 to ₹1080 per share Listing Date - May 8, 2023 Min Lot Size - 13 Share Min Investment - ₹14,040 Learn more

Mr. Ramesh Juneja, Mr. Rajeev Juneja, Mrs. Sheetal Arora

This IPO is a complete Offer For Sale (OFS)

Fourth largest pharmaceutical company in terms of Domestic Sales in FY 2022 in India. “Mankind” is a well-recognized brand in India other brands “Manforce”, “PregaNews”, and “GasOfast” Learn more

Product Categories

Anti-infective Cardiovascular Vitamins/minerals/nutrients Gastrointestinal Respiratory and Anti-diabetic Dermatology and Gynecology Pain/analgesics and Neuro/CNS Respiratory

11,196 medical representatives and 3,195 field managers, as of March 31, 2022 23 manufacturing facilities across India Learn more

Book Running Manager

Kotak Mahindra Capital Company Limited Axis Capital Limited IIFL Securities Ltd Jefferies India Private Limited J.P. Morgan India Private Limited

Mankind Pharma IPO Registrar

KFin Technologies Limited Phone: 04067162222, 04079611000 Email: mankind.ipo@kfintech.com Website: https://karisma.kfintech.com/

Mankind Pharma Financials

[{"selector":"#anim-72a9169f-eefe-450c-8d0c-2a8acc7587fc","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}]

Mankind Pharma Financials - March 31, 2022 (INR Million)

Revenue from Operations Profit After Tax EBITDA Net Cash from Operating Activities EPS 77,815.55 14,529.56 14,483.46 9,197.76 35.78 Learn more

Should I Invest?

[{"selector":"#anim-51effbe0-eb90-437e-94ba-3771c78f4b41","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f7229570-a6a6-4d15-b488-950f81268c50","keyframes":{"transform":["translate3d(135.63637%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-91e36ce5-e1c9-4aa1-8834-275edd89e43c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b892146a-1e1a-4974-b481-c2eb9c56fd60","keyframes":{"transform":["translate3d(-178.99999%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ad00a2e3-f18a-4756-975a-ba47e162ea2d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-57c46fae-64f4-408c-a379-502a4e0421ce","keyframes":{"transform":["translate3d(151.66665%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f64d9863-8e1d-4c16-aba6-b9a3a285acca","keyframes":{"transform":["scale(1)","scale(1.5)","scale(0.95)","scale(1)"],"offset":[0,0.33,0.66,1]},"delay":0,"duration":1450,"easing":"ease-in-out","fill":"both","iterations":1}] Mankind Pharma is in a sweat spot in terms of product portfolio and reach in India and globe The threat of new entrant is low in case of pharma industry Largest domestic formulation business in India with strong brand name Learn more

Mankind Pharma IPO

Should I Invest?

Complete Offer for Sale (OFS) of 40,058,844 Equity Shares.

Face value of each equity share is Rs 1

Subscription Date - Apr 25, 2023 to Apr 27, 2023

Mr. Ramesh Juneja, Mr. Rajeev Juneja, Mrs. Sheetal Arora

Promoters of the company

This IPO is a complete Offer For Sale (OFS)

Company will not receive any of the offer proceeds.

Product Categories

Catagories

Book Running Manager

Mankind Pharma IPO Registrar

Mankind Pharma Financials

Mankind Pharma Financials - March 31, 2022 (INR Million)

Should I Invest?

More Stories Across the Site